000			03578nam a22004095i 4500
001			293023
003			MX-SnUAN
005			20160429155050.0
007			cr nn 008mamaa
008			150903s2011 sz | o |||| 0|eng d
020			_a9783034600941 _99783034600941
024	7		_a10.1007/9783034600941 _2doi
035			_avtls000345166
039		9	_a201509030410 _bVLOAD _c201405050317 _dVLOAD _y201402061330 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRM1-950
100	1		_aSibilia, Maria. _eeditor. _9325273
245	1	0	_aDrugs for HER-2-positive Breast Cancer / _cedited by Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas W. Grunt.
264		1	_aBasel : _bSpringer Basel, _c2011.
300			_ax, 110 páginas _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aMilestones in Drug Therapy
500			_aSpringer eBooks
505	0		_aDrugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt) -- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden) -- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger) -- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello) -- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu) -- Pertuzumab – a HER-2 dimerisation inhibitor – for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni) -- Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).
520			_aGrowth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aZielinski, Christoph C. _eeditor. _9325274
700	1		_aBartsch, Rupert. _eeditor. _9325275
700	1		_aGrunt, Thomas W. _eeditor. _9325276
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783034600934
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-0346-0094-1 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c293023 _d293023